243 related articles for article (PubMed ID: 26691773)
1. Thiamine antivitamins--an opportunity of therapy of fungal infections caused by Malassezia pachydermatis and Candida albicans.
Siemieniuk M; Czyzewska U; Strumilo S; Tylicki A
Mycoses; 2016 Feb; 59(2):108-16. PubMed ID: 26691773
[TBL] [Abstract][Full Text] [Related]
2. Fatty acid profile and influence of oxythiamine on fatty acid content in Malassezia pachydermatis, Candida albicans and Saccharomyces cerevisiae.
Tylicki A; Siemieniuk M; Dobrzyn P; Ziolkowska G; Nowik M; Czyzewska U; Pyrkowska A
Mycoses; 2012 May; 55(3):e106-13. PubMed ID: 22066764
[TBL] [Abstract][Full Text] [Related]
3. Comparative study of the activity and kinetic properties of malate dehydrogenase and pyruvate decarboxylase from Candida albicans, Malassezia pachydermatis, and Saccharomyces cerevisiae.
Tylicki A; Ziolkowska G; Bolkun A; Siemieniuk M; Czerniecki J; Nowakiewicz A
Can J Microbiol; 2008 Sep; 54(9):734-41. PubMed ID: 18772936
[TBL] [Abstract][Full Text] [Related]
4. Oxythiamine improves antifungal activity of ketoconazole evaluated in canine Malassezia pachydermatis strains.
Siemieniuk M; Sosnowska K; Czerniecki J; Czyzewska U; Winnicka K; Tylicki A
Vet Dermatol; 2018 Dec; 29(6):476-e160. PubMed ID: 30251451
[TBL] [Abstract][Full Text] [Related]
5. Phenotypic characterization and in vitro antifungal sensitivity of Candida spp. and Malassezia pachydermatis strains from dogs.
Brito EH; Fontenelle RO; Brilhante RS; Cordeiro RA; Soares Júnior FA; Monteiro AJ; Sidrim JJ; Rocha MF
Vet J; 2007 Jul; 174(1):147-53. PubMed ID: 17188535
[TBL] [Abstract][Full Text] [Related]
6. Modification of thiamine pyrophosphate dependent enzyme activity by oxythiamine in Saccharomyces cerevisiae cells.
Tylicki A; Czerniecki J; Dobrzyn P; Matanowska A; Olechno A; Strumilo S
Can J Microbiol; 2005 Oct; 51(10):833-9. PubMed ID: 16333342
[TBL] [Abstract][Full Text] [Related]
7. Acidophilic actinobacteria synthesised silver nanoparticles showed remarkable activity against fungi-causing superficial mycoses in humans.
Anasane N; Golińska P; Wypij M; Rathod D; Dahm H; Rai M
Mycoses; 2016 Mar; 59(3):157-66. PubMed ID: 26671603
[TBL] [Abstract][Full Text] [Related]
8. Antifungal agent susceptibilities and interpretation of Malassezia pachydermatis and Candida parapsilosis isolated from dogs with and without seborrheic dermatitis skin.
Yurayart C; Nuchnoul N; Moolkum P; Jirasuksiri S; Niyomtham W; Chindamporn A; Kajiwara S; Prapasarakul N
Med Mycol; 2013 Oct; 51(7):721-30. PubMed ID: 23547880
[TBL] [Abstract][Full Text] [Related]
9. Azole susceptibility of Malassezia pachydermatis and Malassezia furfur and tentative epidemiological cut-off values.
Cafarchia C; Iatta R; Immediato D; Puttilli MR; Otranto D
Med Mycol; 2015 Sep; 53(7):743-8. PubMed ID: 26162472
[TBL] [Abstract][Full Text] [Related]
10. Thiamine and selected thiamine antivitamins - biological activity and methods of synthesis.
Tylicki A; Łotowski Z; Siemieniuk M; Ratkiewicz A
Biosci Rep; 2018 Feb; 38(1):. PubMed ID: 29208764
[TBL] [Abstract][Full Text] [Related]
11. Antifungal susceptibility of Malassezia pachydermatis biofilm.
Figueredo LA; Cafarchia C; Otranto D
Med Mycol; 2013 Nov; 51(8):863-7. PubMed ID: 23834283
[TBL] [Abstract][Full Text] [Related]
12. New Therapeutic Candidates for the Treatment of Malassezia pachydermatis -Associated Infections.
Sastoque A; Triana S; Ehemann K; Suarez L; Restrepo S; Wösten H; de Cock H; Fernández-Niño M; González Barrios AF; Celis Ramírez AM
Sci Rep; 2020 Mar; 10(1):4860. PubMed ID: 32184419
[TBL] [Abstract][Full Text] [Related]
13. Assessment of the antifungal susceptibility of Malassezia pachydermatis in various media using a CLSI protocol.
Cafarchia C; Figueredo LA; Favuzzi V; Surico MR; Colao V; Iatta R; Montagna MT; Otranto D
Vet Microbiol; 2012 Oct; 159(3-4):536-40. PubMed ID: 22622336
[TBL] [Abstract][Full Text] [Related]
14. Assessment of in vitro inhibitory activity of hydrogen peroxide on the growth of Malassezia pachydermatis and to compare its efficacy with commercial ear cleaners.
Marrero EJ; Silva FA; Rosario I; Déniz S; Real F; Padilla D; Díaz EL; Acosta-Hernández B
Mycoses; 2017 Oct; 60(10):645-650. PubMed ID: 28557001
[TBL] [Abstract][Full Text] [Related]
15. Combination effects of antifungal nagilactones against Candida albicans and two other fungi with phenylpropanoids.
Kubo I; Muroi H; Himejima M
J Nat Prod; 1993 Feb; 56(2):220-6. PubMed ID: 8463795
[TBL] [Abstract][Full Text] [Related]
16. In vitro antifungal activity of topical and systemic antifungal drugs against Malassezia species.
Carrillo-Muñoz AJ; Rojas F; Tur-Tur C; de Los Ángeles Sosa M; Diez GO; Espada CM; Payá MJ; Giusiano G
Mycoses; 2013 Sep; 56(5):571-5. PubMed ID: 23496653
[TBL] [Abstract][Full Text] [Related]
17. Candida and candidaemia. Susceptibility and epidemiology.
Arendrup MC
Dan Med J; 2013 Nov; 60(11):B4698. PubMed ID: 24192246
[TBL] [Abstract][Full Text] [Related]
18. In vitro antifungal activities of Allium cepa, Allium sativum and ketoconazole against some pathogenic yeasts and dermatophytes.
Shams-Ghahfarokhi M; Shokoohamiri MR; Amirrajab N; Moghadasi B; Ghajari A; Zeini F; Sadeghi G; Razzaghi-Abyaneh M
Fitoterapia; 2006 Jun; 77(4):321-3. PubMed ID: 16690223
[TBL] [Abstract][Full Text] [Related]
19. In vitro and in vivo activity of a killer peptide against Malassezia pachydermatis causing otitis in dogs.
Cafarchia C; Immediato D; Paola GD; Magliani W; Ciociola T; Conti S; Otranto D; Polonelli L
Med Mycol; 2014 May; 52(4):350-5. PubMed ID: 24625672
[TBL] [Abstract][Full Text] [Related]
20. In vitro activity of carvacrol, cinnamaldehyde and thymol combined with antifungals against Malassezia pachydermatis.
Schlemmer KB; Jesus FPK; Tondolo JSM; Weiblen C; Azevedo MI; Machado VS; Botton SA; Alves SH; Santurio JM
J Mycol Med; 2019 Dec; 29(4):375-377. PubMed ID: 31455580
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
